Summary: “Scaling up a group model for therapy isn’t simply a matter of creating another option for people—it’s essential if psychedelics are ever going to be scaled up and delivered to the mainstream in a safe, feasible and affordable manner,” explains NEO.LIFE.
Through interviews with leading psychedelic experts, including MAPS Founder and Executive Director Rick Doblin, Ph.D., author Zoe Cormier compares the cost-effectiveness of psychedelic-assisted therapy in group settings with the more costly, but potentially more effective, option of individualized psychedelic-assisted therapy sessions.
Originally appearing here.
